Description of scientific activity

Monika Arenbergerová is an Associate Professor in the Department of Dermatovenereology at the Third Faculty of Medicine, Charles University, Prague.

Prof. Arenbergerová completed her medical degree at Charles University, Prague. Following completion of research fellowships and physician training at the Free University of Berlin, she obtained a PhD from the Department of Biochemistry and Pathobiochemistry, Charles University. Since 2002, she has been a physician at the Department of Dermatology, Královské Vinohrady University Hospital and a medical teacher at the Third Faculty of Medicine, Charles University, at which she was appointed Vice Dean in 2018.

Dr Arenbergerová has broad interests in dermatology and has authored 58 publications in peer-reviewed journals. Her scientific interests include: Epidemiology of melanoma, immunotherapy of skin cancer, pathophysiology of acne vulgaris and hidradenitis suppurativa. At the same time she is involved in the dermatosurgery and investigates the frequent complications of the surgical interventions in dermatology and aesthetic dermatology.

Selected publications

Arenbergerova M et al. Position statement of the EADV Melanoma Task Force on recommendations for the management of cutaneous melanoma patients during COVID-19. .J Eur Acad Dermatol Venereol. 2021 Jul;35(7):e427-e428.

Arenbergerova M et al. Successful treatment of recalcitrant gluteal hidradenitis suppurativa with brodalumab after anti-TNF failure. Int J Dermatol. 2020 Jun;59(6):733-735

Dahmen RA, Gkalpakiotis S, Mardesicova L, Arenberger P, Arenbergerova M: Deroofing followed by thorough sinus tract excision: a modified surgical approach for hidradenitis suppurativa. J Dtsch Dermatol Ges. 2019 Jul;17(7):698-702.

Selected or ongoing grants/clinical studies

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma

Randomized, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa.

PhD Students

Number of PhD students currently studying: 7

Number of defended students with year of defence: 2 PhD. (2020, 2022)